



Number 80
July 12, 2013

Pharmacy Facts

MassHealth Pharmacy Program

www.mass.gov/masshealth/pharmacy

• Editor: Vic Vangel • Contributors: Chris Burke, Gary Gilmore, Paul Jeffrey, Kim Lenz, James Monahan, Nancy Schiff •

MHDL Update

Below are certain updates to the MassHealth Drug List (MHDL). See the MHDL for a complete listing of updates.

1. Additions

The following newly marketed drugs have been added to the MassHealth Drug List as of July 15, 2013.

- Afinitor Disperz (everolimus tablets for oral suspension)
- desvenlafaxine – **PA**
- Diclegis (doxylamine/pyridoxine delayed-release) – **PA**
- Fulyzaq (crofelemer) – **PA**
- INVOKANA (canagliflozin) – **PA**
- Kadcyca (ado-trastuzumab) – **PA**
- Kazano (alogliptin/metformin) – **PA**
- KYNAMRO (mipomersen) – **PA**
- Liptruzet (ezetimibe/atorvastatin) – **PA**
- NESINA (alogliptin) – **PA**
- Oseni (alogliptin/pioglitazone) – **PA**
- Pomalyst (pomalidomide) – **PA**
- Prolensa (bromfenac 0.07%) – **PA**
- RAVICTI (glycerol phenylbutyrate) – **PA**
- Rescula (unoprostone isopropyl ophthalmic solution) – **PA**
- Signifor (pasireotide) – **PA**
- Suclear Bowel Prep Kit (polyethylene glycol) – **PA**
- Tecfidera (dimethyl fumarate) – **PA**
- TOBI Podhaler (tobramycin inhalation powder)

2. Change in Prior-Authorization Status

The following generic antiemetics will be covered without prior authorization for all quantities, effective July 15, 2013.

- Zofran # (ondansetron 4 mg, 8 mg)
- Zofran ODT # (ondansetron orally disintegrating tablet 4 mg)

3. MassHealth Over-the-Counter Drug List

The following drug has been added to the MassHealth Over-the-Counter Drug List as covered.

- Doxylamine

PA – Prior authorization is required. The prescriber must obtain prior authorization for the drug in order for the pharmacy to receive payment. Note: Prior authorization applies to both the brand-name and the FDA “A”-rated generic equivalent of listed product.

– This designates a brand-name drug with FDA “A”-rated generic equivalents. Prior authorization is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent